Timber Hill’s Myriad Genetics MYGN Stock Holding History

Timber Hill’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-8,037	Closed	-$288K	–	2545
2014 Q4	$274K	Buy	+8,037	New	+$285K	﹤0.01%	2204

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Timber Hill's MYGN Position: Q1 2015 in Review

Timber Hill sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 8,037 shares — an estimated $288K sold.

Timber Hill first reported a position in MYGN in Q4 2014 and held it in 1 quarter. The position peaked at $274K in Q4 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

Timber Hill reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
Timber Hill sold 8,037 Myriad Genetics shares in Q1 2015, an estimated $288K.
Timber Hill first reported a position in Myriad Genetics in Q4 2014 and held it in 1 quarter.
Timber Hill's Myriad Genetics position peaked at $274K in Q4 2014.
251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Timber Hill's 13F filing for Q1 2015, filed 30 Apr 2015.